Literature DB >> 12720176

Cut it out: Managing hepatic abscesses in patients with chronic granulomatous disease.

Li Ern Chen1, Robert K Minkes, Penelope G Shackelford, Steven M Strasberg, Elbert Y Kuo, Jacob C Langer.   

Abstract

BACKGROUND: Hepatic abscesses develop in patients with chronic granulomatous disease (CGD) because the liver is a site of constant bacterial challenge. The authors investigated the roles of drainage and hepatic resection in the management of liver abscesses in CGD patients.
METHODS: Medical records of CGD patients with hepatic abscesses from 1990 to 2001 were reviewed.
RESULTS: There were 6 patients. Mean age of initial abscess was 7.2 years (range, 3 weeks to 18.9 years). All abscesses involved the right lobe of the liver (2 single, 4 multiple). All patients received appropriate antibiotics. Four patients were treated with one to 6 drainage procedures over one to 4 admissions before ultimately undergoing resection. The other 2 patients underwent primary resection without preliminary drainage. Of the 6 resections, 4 were nonanatomic, and 2 were anatomic. There was one major postoperative complication (bleeding) requiring reoperation. There were no recurrences after resection (mean follow-up 4.3 yr). Mean total days in hospital for the treatment of liver abscess was 49 in the preliminary drainage group and 8.5 in the primary resection group. Three patients required admission into the intensive care unit, one after a drainage procedure and 2 after resection.
CONCLUSIONS: For CGD patients with hepatic abscesses, drainage procedures are associated with recurrence and prolonged hospitalization. Primary hepatic resection removing all involved tissue is safe and definitive for the management of this problem. Copyright 2003 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2003        PMID: 12720176     DOI: 10.1016/jpsu.2003.50189

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  7 in total

1.  The Changing Paradigm of Management of Liver Abscesses in Chronic Granulomatous Disease.

Authors:  David M Straughan; Kaitlin C McLoughlin; John E Mullinax; Beatriz E Marciano; Alexandra F Freeman; Victoria L Anderson; Gulbu Uzel; Said C Azoury; Rebecca Sorber; Humair S Quadri; Harry L Malech; Suk See DeRavin; Natasha Kamal; Christopher Koh; Christa S Zerbe; Douglas B Kuhns; John I Gallin; Theo Heller; Steven M Holland; Udo Rudloff
Journal:  Clin Infect Dis       Date:  2018-04-17       Impact factor: 9.079

2.  Alcoholization of pyogenichepatic abscess with absolute alcohol in Bama minipigs.

Authors:  Ru-Gang Zhang; Xiu-Li Zhang; Yun-Sheng Yang
Journal:  Exp Ther Med       Date:  2017-08-24       Impact factor: 2.447

3.  Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.

Authors:  Elizabeth M Kang; Uimook Choi; Narda Theobald; Gilda Linton; Debra A Long Priel; Doug Kuhns; Harry L Malech
Journal:  Blood       Date:  2009-12-01       Impact factor: 22.113

4.  Chronic granulomatous disease: a review of the infectious and inflammatory complications.

Authors:  Eunkyung Song; Gayatri Bala Jaishankar; Hana Saleh; Warit Jithpratuck; Ryan Sahni; Guha Krishnaswamy
Journal:  Clin Mol Allergy       Date:  2011-05-31

5.  Liver abscess in children: a 10-year single centre experience.

Authors:  Roohollah Salahi; Seyed M Dehghani; Heshmatollah Salahi; Ali Bahador; Hamid R Abbasy; Fatemeh Salahi
Journal:  Saudi J Gastroenterol       Date:  2011 May-Jun       Impact factor: 2.485

6.  Successful hepatectomy for hepatic abscess with chronic granulomatous disease: a case report.

Authors:  Ryo Muranushi; Makoto Suzuki; Kenichiro Araki; Norio Kubo; Sayaka Otake; Yutaka Nishida; Takashi Ishige; Hirokazu Arakawa; Hiroyuki Kuwano; Ken Shirabe
Journal:  Surg Case Rep       Date:  2017-04-26

Review 7.  Chronic Granulomatous Disease: a Comprehensive Review.

Authors:  Hsin-Hui Yu; Yao-Hsu Yang; Bor-Luen Chiang
Journal:  Clin Rev Allergy Immunol       Date:  2021-10       Impact factor: 8.667

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.